Pharmacologic monitoring and determinants of intracytoplasmic drug levels

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 3, 2009, Pages 381-386

  Mahon, François Xavier ^a  

^a INSERM   (France)

Author keywords

drug level testing; imatinib; pharmacokinetic

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 1;

CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; EVENT FREE SURVIVAL; HALF LIFE TIME; HUMAN; PATIENT COMPLIANCE; PHILADELPHIA 1 CHROMOSOME; PLASMA PROTEIN BINDING; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOPLASM; DRUG MONITORING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 71849107948     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.09.007     Document Type: Review

References (24)

1. Savage D.G., and Antman K.H. Imatinib mesylate - a new oral targeted therapy. The New England Journal of Medicine 346 (2002) 683-693
2. Goldman J.M., and Melo J.V. Chronic myeloid leukemia - advances in biology and new approaches to treatment. The New England journal of medicine 349 (2003) 1451-1464
3. Hochhaus A., Druker B., Sawyers C., et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 111 3 (2008;1) 1039-1043
4. Druker B.J., Guilhot F., O'Brien S.G., et al. IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. The New England Journal of Medicine 355 23 (2006) 2408-2417
5. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. The Lancet Oncology 8 11 (2007 Nov) 1018-1029 Review
6. Peng B.M., Hayes M., Resta D., et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of Clinical Oncology 22 (2004) 935-942
7. Peng B., Lloyd P., and Schran H. Clinical pharmacokinetics of imatinib. Clinical Pharmacokinetics 444 (2005) 879-894
8. Mahon F.X., Belloc F., Lagarde V., et al. - MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101 (2003) 2368-2373
9. Wang L., Giannoudis A., Lane S., et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clinical Pharmacology and Therapeutics 83 (2008) 258-264
10. Gambacorti-Passerini C., Barni R., le Coutre P., et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. Journal of the National Cancer Institute 92 20 (2000 Oct 18) 1641-1650
11. Picard S., Titier K., Etienne G., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia. Blood 109 (2007) 3496-3499
12. Larson R.A., Druker B.J., Guilhot F., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111 (2008) 4022-4028
13. Gambacorti-Passerini C., Zucchetti M., Russo D., et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clinical Cancer Research 9 (2003) 625-632
14. O'Brien S.G., Meinhardt P., Bond E., et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. British Journal Of Cancer 89 (2003) 1855-1859
15. Bolton A.E., Peng B., Hubert M., et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemotherapy and Pharmacology 53 (2004) 102-106
16. Guilhot F., Hughes T.P., Cortes J., et al. Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia (CML-CP) for 400 mg and 800 mg daily doses (tyrosine kinase dose optimization study [TOPS]). Blood 112 (2008) Abstract 447
17. Forrest D.L., Trainor S., Ryan R., et al. Cytogenic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leukemia Research 33 (2009) 271-275
18. Mahon F.-X., and Molimard M. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia. Leukemia Research 33 8 (2009 Aug) 1147-1148
19. Titier K., Picard S., Ducint D., et al. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Therapeutic Drug Monitoring 27 5 (2005 Oct) 634-640
20. Thomas J., Wang L., Clark R.E., et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104 (2004) 3739-3745
21. White D.L., Saunders V.A., Dang P., et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108 (2006) 697-704
22. White D.L., Saunders V.A., Dang P., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110 (2007) 4064-4072
23. Dulucq S., Bouchet S., Turcq B., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112 5 (2008 Sep 1) 2024-2027
24. Mahon FX, Molimard M, Foryciarz K, et al. Imatinib blood level testing: current perspectives and key questions. Submitted to European Haematology in press.